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Abstract 
Carvacrol, a monoterpene widely present in nature, is commonly used in the food industry and in 
cosmetics, besides to possess a plethora of pharmacological properties; among these also in vitro 
vasorelaxing effects and in vivo hypothensive responses. 
Although in rat aortic rings carvacrol evoked a vasodilatation both in the presence and in the 
absence of endothelium, in preparations with intact endothelial layer its vasoactive response 
appeared markedly improvement.  
Objectives- this study aimed at investigating the mechanism of action responsible for the 
endothelial component of the carvacrol-induced vasorelaxing response observed rat isolated 
aortic rings. 
Key findings- Pharmacological characterization led us to exclude the involvement of NO-pathway 
(neither L-NAME, NO-biosynthesis inhibitor, or ODQ, guanylate cyclase inhibitor, were able to 
modify the vascular effects of carvacrol) and of arachidonic acid cascade (no inhibitor intercepting 
the cascade influenced the endothelial-dependent vasodilatation of the monoterpene). Moreover, 
endothelial TRP channels weren’t also involved, since capsazepine was any effect. 
Finally, endothelial potassium channels were considered as possible targets of carvacrol; indeed, 
two voltage-operated potassium (Kv) channel blockers, 4-aminopyridine and quinine significantly 
reduced carvacrol potency and efficacy indices. 
Conclusions- Kv channels seems to be responsible for vascular effects of the monoterpene typical 
of Labiatae family. 
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Introduction 
Carvacrol, a monoterpene widely present in nature, is the major constituent of the essential oils 
from various aromatic plants, especially of Labiatae family, such as Thymus vulgaris, Origanum 
compactum and Satureja montana. Carvacrol is commonly used in the food industry and in 
cosmetics, as preservative and antioxidant. Interestingly, it possesses also a myriad of 
pharmacological properties, such anti-inflammatory, antibacterial, antitumor and antiplatelet ones 
(1-4).  
Moreover, this monoterpene is reported to exhibit vasorelaxing activity on rat isolated aorta (5) 
and more recently on rat mesenteric arteries (6). Indeed, when administered i.p. to normotensive 
rats, carvacrol induced hypotensive responses (7). Although Peixoto-Neves et al. hypothesized the 
involvement of calcium channels in the concentration-dependent reduction of KCl- or 
phenylephrine-induced contractions, presently no clear mechanism of action has been assigned.  
On the other hand, carvacrol is known also as agonist of transient receptor potential (TRP) cation 
channels, in particular TRPA1 and TRPV3 (8). Interestingly, Earely et al. demonstrated that 
carvacrol concentration-dependently activates calcium influx, produces endothelium-dependent 
vasodilatation and stimulates TRPV3 current in endothelial cells, isolated from cerebral and 
cerebellar arteries (9) . 
Although available data on vascular effects of the monoterpene, to date underlying mechanisms 
the vasorelaxation mediated by carvacrol aren’t again fully understood; particularly this study 
aimed at investigating the mechanism of action responsible for the endothelial component of the 
carvacrol-induced vasorelaxing response observed rat isolated aortic rings. 
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Material and methods 
 
All the experimental procedures were carried out following the guidelines of the European 
Community Council Directive 86-609 and have been approved by the Ethical Committee for animal 
experimentation of Pisa University. To determine a possible vasodilatory mechanism of action, 
carvacrol was tested on isolated thoracic aortic rings of male normotensive Wistar rats (250–350 
g). The rats were sacrificed by an overdose of sodium pentobarbital. The aortae were immediately 
excised and freed of extraneous tissues. Five millimeters wide aortic rings were suspended, under 
a preload of 2g, in 20 ml organ baths, containing Tyrode solution (composition of saline in mM: 
NaCl 136.8; KCl2.95; CaCl2 1.80; MgSO4 1.05; NaH2PO4 0.41; NaHCO311.9; glucose 5.5), 
thermostated at 37°C and continuously gassed with a mixture of O2 (95%) and CO2 (5%). 
Changes in tension were recorded by means of an isometric transducer (Grass FTO3 Basile mod. 
7005), connected with a preamplifier (Buxco Electronics) and with a software of data acquisition 
(BIOPAC Systems Inc., MP 100). After an equilibration period of 60 min, the endothelium 
preservation or removal was confirmed by the administration of acetylcholine (ACh; 10 μM) to KCl 
20mM-precontracted vascular rings. Preparations were considered to possess an intact 
endothelium, when the vasorelaxant response to Ach was greater than 75% of the KCl-induced 
contraction. When required from experiment procedures, the endothelium was removed 
immediately after dissection by gentle rubbing of the aortic lumen with a hypodermic needle. A 
Ach-induced relaxation <5% of the KCl-induced contraction was considered representative of an 
acceptable lack of the endothelial layer; while the organs, showing a relaxation between 5-75 % 
were discarded.  
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About 30–40 min after the endothelium evaluation, the aortic preparations were contracted by 
KCl 20mM and when the contraction reached a stable plateau, three-fold increasing 
concentrations of carvacrol (0.1 μM–100μM) were added cumulatively. Preliminary experiments 
showed that KCl 20mM-induced contractions remained in a stable tonic state for at least 60 min.  
Several sets of experiments have been carried out on rat aortae, as reported in the following 
experimental protocols.  
Experimental Protocol 1 –Absence of endothelium. 
Aortic rings denuded from endothelium layer were contracted by KCl 20mM or KCl 60mM and a 
cumulative concentration-dependent curve was constructed by the addiction of carvacrol (0.1 
μM–100μM)  
Experimental Protocol 2 –Presence of endothelium/Evaluation of NO pathway. 
Aortic rings were incubated with L-NAME 40 µM (NO biosynthesis inhibitor), or ODQ 1 µM 
(guanylate cyclase inhibitor) or the respective vehicles (bidistilled water and ethanol) for 20 
minutes, then KCl 20mM was administered to evoke the contraction and finally a cumulative 
concentration-dependent curve was constructed by the addition of carvacrol (0.1 μM–100μM). 
Experimental Protocol 3 –Presence of endothelium/Evaluation of arachidonic acid cascade. 
In order to evaluate the involvement of arachidonic acid cascade, aristolochic acid 100 µM (A.A., 
phospholipase A2 inhibitor), indomethacin 1 µM (cyclooxygenase inhibitor), baicalein 10 µM 
(lipoxygenase inhibitor) or miconazole 10 μM (citrochrome P450 inhibitor) were incubated 20 
minutes before KCl 20mM-induced contraction and then a cumulative concentration-response 
curve was obtained adding carvacrol (0.1 μM–100μM). 
Experimental Protocol 4- Presence of endothelium/Evaluation of vanilloid receptors. 
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In order to evaluate the involvement of endothelial vanilloid receptors, capsazepine 10 µM (TRPV1 
inhibitor) was incubated 20 minutes before KCl 20mM-induced contraction and then a cumulative 
concentration-response curve was obtained adding carvacrol (0.1 μM–100μM). 
Experimental Protocol 5-Presence of endothelium/Evaluation of potassium channels. 
In order to evaluate the involvement of potassium channels, cumulative concentration-response 
curve was obtained adding carvacrol (0.1 μM–100μM) on rat aortic rings precontracted with KCl 
60mM, a such experimental approach is used to evaluate the involvement of potassium channels. 
Moreover, in order to find the potassium channel involved in the action mechanism of carvacrol, 
tetraethylammonium chloride 10 mM (TEA, blocker of different subtypes of voltage-activated 
potassium channels), glibenclamide 1 μM (blocker of ATP-sensitive potassium channels), 4-
aminopyridine 3mM (4-AP, blocker of many classes of voltage-operated potassium channel), 
apamin 250 nM (small calcium-activated potassium channel (SKCa) blocker), charibdotoxin 100nM 
(big- and intermediate-calcium-activated potassium channel (BKCa/IKCa) blocker) or iberiotoxin 
100 nM (selective BKCa blocker) were added after the achievement of a steady contraction evoked 
by KCl 20mM (eventual increase was expressed as a percentage of the KCl-evoked contractile 
response). After achieving a stable plateau, cumulative concentration-response was obtained 
adding carvacrol (0.1 μM–100μM). 
Data analysis  
The vasorelaxing efficacy of carvacrol was evaluated as the maximal vasodilatory response (Emax), 
evoked by the highest concentration (100µM), expressed as a % of the contractile tone induced by 
KCl 20mM; while the parameter of potency was expressed as pIC50, calculated as the negative 
Logarithm of the molar concentration of carvacrol, evoking a half reduction of the contractile 
tone. 
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The parameters of efficacy and potency were expressed as mean ± standard error, for 6–10 
experiments. ANOVA was selected as statistical analyses, moreover individual differences between 
treatments were evaluated using a post hoc test of Bonferroni. P<0.05 was considered 
representative of a significant statistical difference. Experimental data were analysed by a 
computer fitting procedure (software GraphPad Prism 5.0). 
Drugs 
Carvacrol was purchased from Fluka. All drugs used for investigation of vasorelaxing mechanism of 
carvacrol, acetylcholine and KCl were purchased from Sigma-Aldrich. 
All solutions were freshly diluted immediately before the pharmacological experimental 
procedures from stock solutions using opportune solvents and stored at -20°C.  
Previous experiments showed a complete ineffectiveness of the vehicles. 
 
Results 
Carvacrol produced full vasorelaxing effect on KCl 20mM-precontracted rat aortic preparations, 
both in the presence and in absence of the endothelial layer, although the potency index (pIC50) 
was markedly increased in aortae with endothelium (6.0±0.04) if compared to without it 
(5.2±0.03) (Figure 1). 
Role of NO-pathway 
The NO-biosynthesis inhibitor L-NAME 40 µM, and the guanylate cyclase inhibitor, ODQ 1 µM, 
didn’t antagonize carvacrol-induced vasorelaxant response (Figure 2a; Tab 1). 
Role of arachidonic acid pathway 
Aristolochic acid 100 microM, a phospholipase A2 inhibitor, didn’t significantly antagonize 
carvacrol-induced vasorelaxing effect (Figure 2b). Likely, neither the cyclooxygenase inhibitor 
indomethacin 1 µM, nor the lipoxygenase inhibitor baicalein (10 µM), nor miconazole 10 µM, a 
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cytochrome P450 inhibitor, significantly influenced the vasorelaxing response of carvacrol on 
aortic rings (Figure 2b; Tab. 1). 
Role of TRP receptors 
Capsazepine, a non-selective TRP antagonist, 10 µM didn’t antagonize vasorelaxing effect of 
carvacrol (Figure 2c, Tab.1). 
Role of potassium channels 
In aortic rings without endothelium pre-contracted with KCl 60 mM, carvacrol-induced 
vasorelaxation wasn’t significantly influenced (Figure 3b), suggesting that in these experimental 
conditions potassium channels aren’t engaged. On the other hand, in presence of endothelium, 
the vasorelaxing effect of carvacrol was markedly reduced on aortae pre-contracted with KCl 
60mM, indeed both pIC50 and efficacy were significantly decreased, suggesting a pivotal role of 
endothelium potassium channels (Tab.1, Figure 3a).  
-Involvement of SKCa/IKCa/BKCa channels 
Neither TEA 10 mM, nor iberiotoxin 100nM nor charibdotoxin 100nM nor apamine 250nM 
significantly antagonized the vascular effects of the monoterpene (Figure 4a). 
-Involvement of ATP –sensitive potassium channels 
KATP channels didn’t seem involved in the endothelium-dependent vasorelaxing effects of 
carvacrol, since glibenclamide 10µM didn’t modify its vascular action (Figure 4b , Tab.1). 
-Involvement of voltage-gated potassium channels. 
4-AP 3mM, a non-selective Kv blocker, markedly antagonized the endothelium-mediated 
vasorelaxing response of carvacrol, reducing its potency index to 4.8±0.08 (Figure 4c, Tab. 1). 
Further, another non-selective blocker of Kv channels, indeed quinine 200 µM also significantly 
antagonized the carvacrol action. 
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Discussion 
Carvacrol, a monoterpene of natural origin, induces vasorelaxation in isolated vessels from rat, 
observed on mesenteric arteries, mainly through an inhibition of calcium-influx, with a 
participation of the TRP channels (6). Previous studies on smooth muscle and vascular beds also 
reported vasoactive profile for this monoterpene, as well as a dose-dependent hypotension and 
bradycardia on anaesthetized rats (5,7). 
In this paper, our attention was focused on the endothelium-dependent vascular effect of the 
monoterpene; indeed in the preparations with intact endothelium, carvacrol produced more 
potent vasorelaxation on the KCl20mM-precontracted aortae that in preparations without 
endothelium (Fig 1; Tab1); suggesting a relevant contribute of some mediators of endothelial 
origin in its vascular effects. Indeed, endothelial cells regulate vascular tone by releasing various 
contracting and relaxing factors including nitric oxide (NO), arachidonic acid metabolites, reactive 
oxygen species and vasoactive peptides (10). It is well-known that NO-pathway plays a pivotal role 
in the homeostasis of vascular tone, nonetheless in our set of experiments treatment with L-NAME 
or ODQ didn’t modify vascular profile of the monoterpene (Fig. 2a, tab.1), leading to hypothesize 
that carvacrol-mediated endothelial mechanism is independent from NO biosynthesis or release. 
This result is in agreement with previous observations of Peixoto-Neves et al. (5). 
On the other hand, arachidonic acid can be a precursor at endothelial level of several vasoactive 
mediators playing a critical role in the cardiovascular functions. Particularly, it can be metabolized 
by means of cyclooxygenase enzyme in order to produce prostacyclin (PGI2), by means 
lipoxygenase can be synthetized hydroperoxytetraenoic acids (HPETE), precursors of leucotriens 
and by means cytochrome P450 monooxygenase can be obtained epoxyeicosatrienoic derivatives 
(11, 12, 13). 
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Nevertheless, aristolochic acid (100 µM), an inhibitor of phospholipase A2 that prevents the 
arachidonic acid mobilization from cell membrane, didn’t antagonize vascular effect of carvacrol; 
similarly to indomethacin (1 µM), an inhibitor of cyclooxygenase enzyme, baicalein (10 µM) a 
flavonoid endowed with lipoxygenase inhibitor activity and miconazole (10 µM) an anti-mycotic 
derivative used to block cytochrome P450 (Fig.2b, tab.1), suggesting that arachidonic cascade was 
not involved in the endothelial response of carvacrol. 
Recently, the participation of TRP channels has been demonstrated on mesenteric arteries, 
however, the subtype of TRP channel involved is yet missing.  
At endothelium level have been described several subtype of TRP channels, in particular of 
vanilloid subtypes, TRPV1, TRPV2, TRPV3 (14, 15). In this study capsazepine, a non-selective 
antagonist that has been used in order to evaluate the role of endothelial vanilloid receptors, 
didn’t inhibit the carvacrol-induced vasorelaxing response; leading to speculate that in these 
experimental conditions, unlikely to mesenteric arteries (6), TRP channel has a marginal role.  
Vascular function can be also regulated through several type of potassium channels, expressed on 
sarcolemmal but also on endothelial layer. On this regard the presence of calcium-dependent 
potassium channel endowed with different grade of conduction, big (BKCa), intermediate (IKCa) 
and small (SKCa), ATP-sensitive (KATP) and voltage-operated potassium channels (Kv) have been 
widely reported (16).  
The involvement of potassium channels has been confirmed using KCl60mM to induce 
vasocontraction; indeed, a high level of depolarisation (induced by KCl60mM) is expected to 
induce a dramatic reduction of the parameters of potency and efficacy of drugs activating 
potassium channels (17) (Fig. 3, tab.1). Unlikely, in aortic preparations deprived of endothelium 
layer high membrane depolarization didn’t influence neither potency nor efficacy of carvacrol, 
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suggesting that potassium channels are involved only in the endothelium-dependent 
vasodilatation of monoterpene. 
Calcium-activated potassium channels are discarded, indeed selective and non-selective blockers 
were without effect on vascular action of carvacrol (Fig. 4a, tab.1), similarly, carvacrol didn’t open 
endothelial KATP channels (Fig. 4b, tab.1). 
Finally, voltage-operated one seemed to be the responsible for vasoactive profile of carvacrol, as 
demonstrated by using 4-AP and quinine, both Kv inhibitors (Fig. 4c, tab.1). 
Concluding, endothelium-dependent action mechanism through which carvacrol produces a 
vasorelaxation on in vitro preparations of rat aortic rings is related to the engagement of voltage-
operated potassium channels; indeed their opening provoke an hyperpolarization with 
consequent relaxation of aortic smooth muscle. 
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Legends  
Table 1 Potency and Efficacy indexes of carvacrol obtained pre-treating aortic preparations with 
intact endothelial layer. 
Figure 1. Concentration-dependent curve obtained with carvacrol in the presence and in the 
absence of endothelium on rat aortic rings. 
Figure 2. Concentration-dependent curve obtained with carvacrol, a) in the presence and in the 
absence of NO-pathway inhibitors (L-NAME and ODQ); b) in the presence and in the absence of 
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arachidonic acid cascade (Aristolochic acid, Indometacin, Baicalein, Miconazole); c) in the presence 
and in the absence of Capsazepine. 
Figure 3. Concentration-dependent curve obtained with carvacrol, a) on aortic rings with intact 
endothelium pre-contracted by KCl 20mM or KCl 60mM; b) on aortic rings without endothelium 
pre-contracted by KCl 20mM or KCl 60 mM. 
Figure 4. Concentration-dependent curve obtained with carvacrol, a) in the presence and in the 
absence of calcium-activated potassium channel blockers (TEA, ChTX, IbTX and Apamin); b) in the 
presence and in the absence of ATP-sensitive potassium channel blockers (Glibenclamide); c) in 
the presence and in the absence of voltage-operated potassium channel blockers (4-AP and 
quinine). 
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Table 1 
 
Pharmacological treatment (*) pIC50 (M) Efficacy (%) 
Vehicle (without Endo) 5.20±0.03 full 
KCl60mM-contraction (without Endo) 4.90±0.1 full 
Vehicle 6.00±0.04 93±2 
KCl60mM-contraction 4.99±0.03 95±2 
L-NAME 40 µM 5.97±0.10 Full 
ODQ 1µM 5.74±0.08 full 
A.A. 100 µM 5.71±0.10 92±12 
Indometacin 1µM 5.72±0.06 98±2 
Baicalein 10µM 5.61±0.09 full 
Miconazole 10µM 5.44±0.15 85±15 
TEA 10mM 6.20±0.15 93±8 
Caribdotoxin 100nM 5.66±0.12 full 
Iberiotoxin 100nM 6.44±0.15 full 
Apamin 250nM 5.32±0.05 94±15 
Glybenclamide 1µM 6.12±0.16 85±4 
Capsazepine 1µM 6.28±0.15 95±5 
4-AP 3mM 4.93±0.04 91±3 
Quinine 200µM 5.32±0.05 full 
(*) All pharmacological treatments have been executed on aortic preparations with intact endothelial layer, 
with the exception of the first and second ones, as indicated in table. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
 
